Author: Sunita Pirmal, PharmD, BCPS + InpharmD AI
INTRODUCTION BY INPHARMD RESEARCHER
Literature on the concomitant use of psychedelics (such as LSD, psilocybin, and MDMA) and antidepressants or antipsychotics is limited to pharmacokinetic trials and systematic reviews, mostly based on clinical trials with healthy patients or case reports. MDMA imparts its effect on serotonin, norepinephrine, and dopamine, while psilocybin and LSD impact serotonergic neurotransmission, resulting in the potential for serotonin syndrome when these agents are coadministered with antidepressants.
Mechanistically, 3,4-methylenedioxymethamphetamine (MDMA) is described as an amphetamine derivative, operating in 2 different mechanisms to increase the central nervous system's serotonin concentration. At a typical dose of 1.7 mg/kg, MDMA promotes serotonin neuronal efflux by altering the chemical gradient that moves serotonin away from the intercellular space and influences the same reuptake transporter used by serotonin reuptake inhibitors (SSRIs). Additionally, MDMA is metabolized by and can inhibit CYP2D6 which allows some SSRIs to have the potential to inhibit MDMA metabolism. However, there is a lack of data investigating the drug-drug interaction (DDI) between SSRIs and MDMA given the potential of both drugs to raise synaptic cleft serotonin levels and the potential pharmacokinetic interaction if the SSRI is a potent CYP450 2D6 inhibitor. It has been proposed that many of the symptoms of MDMA toxicity may overlap with serotonin syndrome. This may result in some cases of sero...
READ MORE→
A search of the published medical literature revealed
3 studies investigating the researchable question:
What is the harm (from a drug-drug interaction standpoint) in patients who choose to take either LSD, Psilocybin, or MDMA alongside their antidepressant or antipsychotic medication?
Level of evidence
C - Multiple studies with limitations or conflicting results
READ MORE→
[1] Dobry Y, Rice T, Sher L. Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. Int J Adolesc Med Health. 2013;25(3):193-199. doi:10.1515/ijamh-2013-0052
[2] Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022;239(6):1945-1976. doi:10.1007/s00213-022-06083-y
[3] Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: A systematic review. J ...
Author: Open AI GPT
Drug-Drug Interactions: LSD, Psilocybin, MDMA, and Antidepressants/Antipsychotics
The interaction of substances like LSD (Lysergic acid diethylamide), Psilocybin, and MDMA (3,4-Methylenedioxymethamphetamine) with antidepressants or antipsychotics is an important consideration in behavioral health settings. Below is an overview of potential interactions and concerns:
LSD and Psilocybin
LSD and Psilocybin are psychedelics that primarily exert their psychedelic effects through the serotonin (5-HT) receptor system, particularly 5-HT2A receptor agonism. Due to their mechanism of action, theoretically, there may be some interaction with serotonergic medications, though clinically significant drug-drug interactions (DDIs) seem minimal based on existing data:
-
Antidepressants (SSRIs, SNRIs, TCAs, MAOIs):
-
SSRIs/SNRIs: Chronic use of SSRIs (Selective Serotonin Reuptake Inhibitors) may blunt the effects of LSD and Psilocybin by downregulating 5-HT2A receptors. This could reduce the intensity of the psychedelic experience, but no significant harm or dangerous interactions have been documented. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) may have similar effects.
-
MAO Inhibitors: Combining MAOIs with psychedelics increases serotonergic activity and could theoretically increase the risk of serotonin syndrome, a potentially life-threatening condition. Though anecdotal reports are rare, caution is advised.
-
Antipsychotics:
- Antipsychotic medications (such as atypical antipsychotics like olanzapine or risperidone) often antagonize serotonin receptors, particularly 5-HT2A, potentially reducing or even counteracting the effects of LSD or Psilocybin. Antipsychotics might also be used to manage adverse reactions like psychosis following LSD or Psilocybin use.
- Overall, no major safety concerns have been documented in combining psychedelics with antipsychotics, though the effectiveness of either drug might be impacted.
MDMA (Ecstasy)
MDMA has a more complex mechanism of action compared to classical psychedelics. It increases the release of serotonin, dopamine, and norepinephrine. This poses more risk when used alongside other medications that also affect these neurotransmitter systems, particularly serotonergic agents.
-
Antidepressants:
-
SSRIs/SNRIs: SSRIs and SNRIs block the reuptake of serotonin, which can reduce the subjective effects of MDMA. However, combining MDMA with SSRIs/SNRIs can increase the risk of serotonin syndrome, especially if MDMA is taken in high doses. Symptoms of serotonin syndrome include agitation, confusion, rapid heart rate, hypertension, hyperthermia, tremor, and muscle rigidity, and it requires immediate medical attention.
-
MAO Inhibitors (MAOIs): Combining MDMA with MAOIs presents a very high risk of serotonin syndrome and is contraindicated. The combination can lead to dangerously high levels of serotonin in the brain. This is considered a highly dangerous interaction.
-
Antipsychotics:
- Antipsychotics like risperidone and quetiapine mitigate some of the actions of MDMA by blocking serotonin and dopamine receptors. This can reduce the effects of MDMA to some degree. There is no clear evidence of harmful DDIs between MDMA and antipsychotics, but antipsychotics may reduce the euphoric and stimulant effects of MDMA.
Conclusion
Both LSD and Psilocybin carry relatively low risk of harmful drug-drug interactions with antidepressants or antipsychotics, though the combination may reduce their effects or efficacy. The more serious concern lies with MDMA, particularly in the presence of serotonergic medications like SSRIs, SNRIs, and especially MAO Inhibitors. In this case, serotonin syndrome could be life-threatening.
Careful consideration of medication regimens is necessary for any patient combining these substances. Patients should be educated about the potential risks and cautioned against combining MDMA with serotonergic drugs like MAOIs due to the high risk for serotonin syndrome.
Disclaimer: The information provided here is for educational purposes and does not substitute for professional medical advice. Patients should always consult their healthcare professional before combining medications or other substances.